消化

订阅

MedSci主页 / 所有栏目 / 消化

GUT：HER2阳性转移性胃癌患者曲妥珠单抗耐药机制研究进展

2018-10-08 MedSci MedSci原创

曲妥珠单抗HER2耐药
关注

研究认为通过肿瘤DNA测序为深入了解HER2阳性转移性胃癌患者曲妥珠单抗耐药机制的研究提供了新思路

近日研究人员通过对曲妥珠单抗耐药性监测，探讨HER2阳性转移性胃癌(mGC)患者不良应答率和快速耐药的机制。

研究人员对78名患者的血浆和组织活检标本进行416个临床相关基因的靶向测序，随后对24例HER 2阳性患者的97份血浆标本进行纵向分析，追踪治疗过程中的耐药情况并验证候选耐药基因。

研究发现，基于靶向测序的HER 2基因体细胞拷贝数改变(SCNA)检测结果与荧光原位杂交数据高度一致， HER 2阳性SCNA比血浆癌胚抗原水平可更好地预测肿瘤缩小或进展。与基线相比，大多数先天性曲妥珠单抗耐药患者在治疗过程中表现出较高的HER 2 SCNA，而获得性抵抗患者HER2 SCNA水平下降。在基线6名以及治疗过程中5名曲妥珠单抗抵抗患者中，PIK3CA突变在先天性抵抗人群中最常见，而非ERBB2/4突变。基线血浆PIK3CA/R1/C3或ERBB2/4突变患者其无进展生存期显著缩短。此外，NF1突变与曲妥珠单抗耐药相关。临床中发现，HER2和MEK/ERK抑制剂联合应用可克服曲妥珠单抗的耐药性。

研究认为通过肿瘤DNA测序为深入了解HER2阳性转移性胃癌患者曲妥珠单抗耐药机制的研究提供了新思路。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2056188, encodeId=c06920561880b, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue May 07 02:31:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971354, encodeId=4ab819e13547c, content=<a href='/topic/show?id=ee288039ece' target=_blank style='color:#2F92EE;'>#耐药机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80397, encryptionId=ee288039ece, topicName=耐药机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 10 01:31:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735288, encodeId=85c61e35288a4, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Tue Apr 16 09:31:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648132, encodeId=973316481325e, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Thu Jul 11 18:31:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769659, encodeId=8b7c1e6965984, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83234, encryptionId=900b8323461, topicName=胃癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=377c38086944, createdName=huhuaidong400, createdTime=Thu Jan 17 05:31:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768919, encodeId=69da1e6891900, content=<a href='/topic/show?id=e0a48e418e' target=_blank style='color:#2F92EE;'>#HER2阳性转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8741, encryptionId=e0a48e418e, topicName=HER2阳性转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=659e37938470, createdName=ms3046638856685384, createdTime=Wed Jan 30 22:31:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308516, encodeId=0ce41308516e7, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381094, encodeId=65b2138109492, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386431, encodeId=4e7213864310a, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348482, encodeId=2d8d34848270, content=感谢小编为我们准备了如此丰盛的精神大餐，同时也向作者致谢！认真学习了，点赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Oct 08 12:27:06 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2019-05-07 hbwxf

    #机制研究#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2056188, encodeId=c06920561880b, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue May 07 02:31:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971354, encodeId=4ab819e13547c, content=<a href='/topic/show?id=ee288039ece' target=_blank style='color:#2F92EE;'>#耐药机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80397, encryptionId=ee288039ece, topicName=耐药机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 10 01:31:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735288, encodeId=85c61e35288a4, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Tue Apr 16 09:31:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648132, encodeId=973316481325e, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Thu Jul 11 18:31:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769659, encodeId=8b7c1e6965984, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83234, encryptionId=900b8323461, topicName=胃癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=377c38086944, createdName=huhuaidong400, createdTime=Thu Jan 17 05:31:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768919, encodeId=69da1e6891900, content=<a href='/topic/show?id=e0a48e418e' target=_blank style='color:#2F92EE;'>#HER2阳性转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8741, encryptionId=e0a48e418e, topicName=HER2阳性转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=659e37938470, createdName=ms3046638856685384, createdTime=Wed Jan 30 22:31:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308516, encodeId=0ce41308516e7, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381094, encodeId=65b2138109492, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386431, encodeId=4e7213864310a, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348482, encodeId=2d8d34848270, content=感谢小编为我们准备了如此丰盛的精神大餐，同时也向作者致谢！认真学习了，点赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Oct 08 12:27:06 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2019-09-10 zhaojie88

    #耐药机制#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2056188, encodeId=c06920561880b, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue May 07 02:31:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971354, encodeId=4ab819e13547c, content=<a href='/topic/show?id=ee288039ece' target=_blank style='color:#2F92EE;'>#耐药机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80397, encryptionId=ee288039ece, topicName=耐药机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 10 01:31:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735288, encodeId=85c61e35288a4, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Tue Apr 16 09:31:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648132, encodeId=973316481325e, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Thu Jul 11 18:31:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769659, encodeId=8b7c1e6965984, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83234, encryptionId=900b8323461, topicName=胃癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=377c38086944, createdName=huhuaidong400, createdTime=Thu Jan 17 05:31:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768919, encodeId=69da1e6891900, content=<a href='/topic/show?id=e0a48e418e' target=_blank style='color:#2F92EE;'>#HER2阳性转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8741, encryptionId=e0a48e418e, topicName=HER2阳性转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=659e37938470, createdName=ms3046638856685384, createdTime=Wed Jan 30 22:31:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308516, encodeId=0ce41308516e7, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381094, encodeId=65b2138109492, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386431, encodeId=4e7213864310a, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348482, encodeId=2d8d34848270, content=感谢小编为我们准备了如此丰盛的精神大餐，同时也向作者致谢！认真学习了，点赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Oct 08 12:27:06 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2019-04-16 limedical1985

    #转移性胃癌#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2056188, encodeId=c06920561880b, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue May 07 02:31:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971354, encodeId=4ab819e13547c, content=<a href='/topic/show?id=ee288039ece' target=_blank style='color:#2F92EE;'>#耐药机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80397, encryptionId=ee288039ece, topicName=耐药机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 10 01:31:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735288, encodeId=85c61e35288a4, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Tue Apr 16 09:31:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648132, encodeId=973316481325e, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Thu Jul 11 18:31:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769659, encodeId=8b7c1e6965984, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83234, encryptionId=900b8323461, topicName=胃癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=377c38086944, createdName=huhuaidong400, createdTime=Thu Jan 17 05:31:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768919, encodeId=69da1e6891900, content=<a href='/topic/show?id=e0a48e418e' target=_blank style='color:#2F92EE;'>#HER2阳性转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8741, encryptionId=e0a48e418e, topicName=HER2阳性转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=659e37938470, createdName=ms3046638856685384, createdTime=Wed Jan 30 22:31:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308516, encodeId=0ce41308516e7, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381094, encodeId=65b2138109492, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386431, encodeId=4e7213864310a, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348482, encodeId=2d8d34848270, content=感谢小编为我们准备了如此丰盛的精神大餐，同时也向作者致谢！认真学习了，点赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Oct 08 12:27:06 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2019-07-11 linlin2320

    #曲妥珠#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2056188, encodeId=c06920561880b, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue May 07 02:31:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971354, encodeId=4ab819e13547c, content=<a href='/topic/show?id=ee288039ece' target=_blank style='color:#2F92EE;'>#耐药机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80397, encryptionId=ee288039ece, topicName=耐药机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 10 01:31:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735288, encodeId=85c61e35288a4, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Tue Apr 16 09:31:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648132, encodeId=973316481325e, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Thu Jul 11 18:31:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769659, encodeId=8b7c1e6965984, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83234, encryptionId=900b8323461, topicName=胃癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=377c38086944, createdName=huhuaidong400, createdTime=Thu Jan 17 05:31:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768919, encodeId=69da1e6891900, content=<a href='/topic/show?id=e0a48e418e' target=_blank style='color:#2F92EE;'>#HER2阳性转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8741, encryptionId=e0a48e418e, topicName=HER2阳性转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=659e37938470, createdName=ms3046638856685384, createdTime=Wed Jan 30 22:31:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308516, encodeId=0ce41308516e7, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381094, encodeId=65b2138109492, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386431, encodeId=4e7213864310a, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348482, encodeId=2d8d34848270, content=感谢小编为我们准备了如此丰盛的精神大餐，同时也向作者致谢！认真学习了，点赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Oct 08 12:27:06 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2019-01-17 huhuaidong400

    #胃癌患者#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2056188, encodeId=c06920561880b, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue May 07 02:31:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971354, encodeId=4ab819e13547c, content=<a href='/topic/show?id=ee288039ece' target=_blank style='color:#2F92EE;'>#耐药机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80397, encryptionId=ee288039ece, topicName=耐药机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 10 01:31:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735288, encodeId=85c61e35288a4, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Tue Apr 16 09:31:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648132, encodeId=973316481325e, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Thu Jul 11 18:31:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769659, encodeId=8b7c1e6965984, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83234, encryptionId=900b8323461, topicName=胃癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=377c38086944, createdName=huhuaidong400, createdTime=Thu Jan 17 05:31:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768919, encodeId=69da1e6891900, content=<a href='/topic/show?id=e0a48e418e' target=_blank style='color:#2F92EE;'>#HER2阳性转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8741, encryptionId=e0a48e418e, topicName=HER2阳性转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=659e37938470, createdName=ms3046638856685384, createdTime=Wed Jan 30 22:31:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308516, encodeId=0ce41308516e7, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381094, encodeId=65b2138109492, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386431, encodeId=4e7213864310a, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348482, encodeId=2d8d34848270, content=感谢小编为我们准备了如此丰盛的精神大餐，同时也向作者致谢！认真学习了，点赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Oct 08 12:27:06 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2019-01-30 ms3046638856685384

    #HER2阳性转移性胃癌#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2056188, encodeId=c06920561880b, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue May 07 02:31:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971354, encodeId=4ab819e13547c, content=<a href='/topic/show?id=ee288039ece' target=_blank style='color:#2F92EE;'>#耐药机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80397, encryptionId=ee288039ece, topicName=耐药机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 10 01:31:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735288, encodeId=85c61e35288a4, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Tue Apr 16 09:31:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648132, encodeId=973316481325e, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Thu Jul 11 18:31:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769659, encodeId=8b7c1e6965984, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83234, encryptionId=900b8323461, topicName=胃癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=377c38086944, createdName=huhuaidong400, createdTime=Thu Jan 17 05:31:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768919, encodeId=69da1e6891900, content=<a href='/topic/show?id=e0a48e418e' target=_blank style='color:#2F92EE;'>#HER2阳性转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8741, encryptionId=e0a48e418e, topicName=HER2阳性转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=659e37938470, createdName=ms3046638856685384, createdTime=Wed Jan 30 22:31:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308516, encodeId=0ce41308516e7, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381094, encodeId=65b2138109492, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386431, encodeId=4e7213864310a, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348482, encodeId=2d8d34848270, content=感谢小编为我们准备了如此丰盛的精神大餐，同时也向作者致谢！认真学习了，点赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Oct 08 12:27:06 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2018-10-10 闆锋旦

    #HER2阳性#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2056188, encodeId=c06920561880b, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue May 07 02:31:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971354, encodeId=4ab819e13547c, content=<a href='/topic/show?id=ee288039ece' target=_blank style='color:#2F92EE;'>#耐药机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80397, encryptionId=ee288039ece, topicName=耐药机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 10 01:31:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735288, encodeId=85c61e35288a4, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Tue Apr 16 09:31:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648132, encodeId=973316481325e, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Thu Jul 11 18:31:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769659, encodeId=8b7c1e6965984, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83234, encryptionId=900b8323461, topicName=胃癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=377c38086944, createdName=huhuaidong400, createdTime=Thu Jan 17 05:31:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768919, encodeId=69da1e6891900, content=<a href='/topic/show?id=e0a48e418e' target=_blank style='color:#2F92EE;'>#HER2阳性转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8741, encryptionId=e0a48e418e, topicName=HER2阳性转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=659e37938470, createdName=ms3046638856685384, createdTime=Wed Jan 30 22:31:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308516, encodeId=0ce41308516e7, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381094, encodeId=65b2138109492, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386431, encodeId=4e7213864310a, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348482, encodeId=2d8d34848270, content=感谢小编为我们准备了如此丰盛的精神大餐，同时也向作者致谢！认真学习了，点赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Oct 08 12:27:06 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2018-10-10 mashirong

    #研究进展#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2056188, encodeId=c06920561880b, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue May 07 02:31:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971354, encodeId=4ab819e13547c, content=<a href='/topic/show?id=ee288039ece' target=_blank style='color:#2F92EE;'>#耐药机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80397, encryptionId=ee288039ece, topicName=耐药机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 10 01:31:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735288, encodeId=85c61e35288a4, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Tue Apr 16 09:31:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648132, encodeId=973316481325e, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Thu Jul 11 18:31:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769659, encodeId=8b7c1e6965984, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83234, encryptionId=900b8323461, topicName=胃癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=377c38086944, createdName=huhuaidong400, createdTime=Thu Jan 17 05:31:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768919, encodeId=69da1e6891900, content=<a href='/topic/show?id=e0a48e418e' target=_blank style='color:#2F92EE;'>#HER2阳性转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8741, encryptionId=e0a48e418e, topicName=HER2阳性转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=659e37938470, createdName=ms3046638856685384, createdTime=Wed Jan 30 22:31:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308516, encodeId=0ce41308516e7, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381094, encodeId=65b2138109492, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386431, encodeId=4e7213864310a, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348482, encodeId=2d8d34848270, content=感谢小编为我们准备了如此丰盛的精神大餐，同时也向作者致谢！认真学习了，点赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Oct 08 12:27:06 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2018-10-10 1249842em09(暂无昵称)

    #转移性#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2056188, encodeId=c06920561880b, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue May 07 02:31:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971354, encodeId=4ab819e13547c, content=<a href='/topic/show?id=ee288039ece' target=_blank style='color:#2F92EE;'>#耐药机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80397, encryptionId=ee288039ece, topicName=耐药机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 10 01:31:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735288, encodeId=85c61e35288a4, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Tue Apr 16 09:31:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648132, encodeId=973316481325e, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Thu Jul 11 18:31:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769659, encodeId=8b7c1e6965984, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83234, encryptionId=900b8323461, topicName=胃癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=377c38086944, createdName=huhuaidong400, createdTime=Thu Jan 17 05:31:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768919, encodeId=69da1e6891900, content=<a href='/topic/show?id=e0a48e418e' target=_blank style='color:#2F92EE;'>#HER2阳性转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8741, encryptionId=e0a48e418e, topicName=HER2阳性转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=659e37938470, createdName=ms3046638856685384, createdTime=Wed Jan 30 22:31:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308516, encodeId=0ce41308516e7, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381094, encodeId=65b2138109492, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386431, encodeId=4e7213864310a, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Oct 10 02:31:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348482, encodeId=2d8d34848270, content=感谢小编为我们准备了如此丰盛的精神大餐，同时也向作者致谢！认真学习了，点赞！, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Oct 08 12:27:06 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2018-10-08 ylzr123

    感谢小编为我们准备了如此丰盛的精神大餐，同时也向作者致谢！认真学习了，点赞！

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

JAHA：曲妥珠单抗能否用于射血分数降低的乳腺癌患者？

由此可见，接受曲妥珠单抗治疗的乳腺癌患者基线心功能受损的女性LVEF下降风险较高，并且更常发生症状性心力衰竭。虽然可以考虑使用曲妥珠单抗，但这些患者应由心脏病专家共同管理。

Lancet Oncol:生物类似药的曲折前行—LILAC研究

生物类似药的研发和上市也存在严格的标准，需要证明类似药与参照药的疗效是等效的。在乳腺癌的治疗中，已有多项3期研究证实了几种生物类似药与曲妥珠单抗参照药的临床相似性，但尚未有研究评估从曲妥珠单抗转换到生物类似药后的疗效如何。

Lancet oncol：ABP980，曲妥珠单抗的生物类似物，用于HER2阳性的乳腺癌患者的效果和安全性，与曲妥珠单抗的不相上下

ABP980是曲妥珠单抗的生物类似物，与曲妥珠单抗具有相似的分析、功能和药代动力学。现研究人员在多个国家的97个研究中心开展一随机的、多中心、双盲、活性对照的等效试验，对比ABP980与曲妥珠单抗用于HER2阳性的早期乳腺癌的效果和安全性。招募年满18岁的组织学确诊的HER2阳性的侵袭性早期乳腺癌患者，ECOG表现评分0-1分、计划进行采样手术切除肿瘤以及前哨或腋窝淋巴结清扫和新辅助化疗。经过4个

Lancet Oncol：曲妥珠单抗+帕妥珠单抗+化疗不能延长HER2阳性转移性胃或胃食管交界癌患者总生存期

研究认为曲妥珠单抗+帕妥珠单抗+化疗一线治疗HER2阳性转移性胃或胃食管交界癌的疗效不显著

Unum Therapeutics宣布研究性新药（IND）申请：抗体偶联T细胞受体（ACTR）细胞疗法和曲妥珠单抗联合治疗HER2阳性晚期癌症

Unum的新型专利技术抗体偶联T细胞受体（antibody-coupled T cell receptor， ACTR）是一种通用的工程细胞疗法。

Ann Oncol：HER-2无扩增早期乳腺癌患者，曲妥珠单抗能减少转移复发风险？

2018年8月，发表在《Ann Oncol》的一项由比利时、德国、法国学者进行的研究，考察了曲妥珠单抗vs 观察能否减少HER-2无扩增早期乳腺癌患者的转移复发风险。